<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68174</article-id><article-id pub-id-type="doi">10.7554/eLife.68174</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-205432"><name><surname>Pasternak</surname><given-names>Alexander O</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4097-4251</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230024"><name><surname>Vroom</surname><given-names>Jelmer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230029"><name><surname>Kootstra</surname><given-names>Neeltje A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9429-7754</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230030"><name><surname>Wit</surname><given-names>Ferdinand WNM</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230031"><name><surname>de Bruin</surname><given-names>Marijn</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230032"><name><surname>De Francesco</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230033"><name><surname>Bakker</surname><given-names>Margreet</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230034"><name><surname>Sabin</surname><given-names>Caroline A</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230035"><name><surname>Winston</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230036"><name><surname>Prins</surname><given-names>Jan M</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230037"><name><surname>Reiss</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230038"><name><surname>Berkhout</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><on-behalf-of>on behalf of The Co-morBidity in Relation to Aids (COBRA) Collaboration</on-behalf-of><aff id="aff1"><institution content-type="dept">Medical Microbiology</institution>, <institution>Amsterdam UMC, University of Amsterdam</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff2"><institution content-type="dept">Experimental Immunology</institution>, <institution>Amsterdam UMC, University of Amsterdam</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff3"><institution content-type="dept">Global Health</institution>, <institution>Amsterdam UMC, University of Amsterdam</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff4"><institution content-type="dept">Radboud Institute for Health Sciences</institution>, <institution>Radboud University Medical Center</institution>, <addr-line><named-content content-type="city">Nijmegen</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff5"><institution content-type="dept">Institute for Global Health</institution>, <institution>University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">Medicine</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><institution content-type="dept">Internal Medicine</institution>, <institution>Amsterdam UMC, University of Amsterdam</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>New Caledonia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-90350"><name><surname>Overbaugh</surname><given-names>Julie M</given-names></name><role>Reviewing editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>a.o.pasternak@amsterdamumc.nl</email> (AP);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>08</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e68174</elocation-id><history><date date-type="received"><day>07</day><month>03</month><year>2021</year></date><date date-type="accepted"><day>07</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Pasternak et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Pasternak et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68174-v1.pdf"/><abstract><p><bold>BACKGROUND:</bold> It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress HIV replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).</p><p><bold>METHODS:</bold> CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n=100, n=124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4<sup>+</sup> count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically-measured adherence to ART.</p><p><bold>RESULTS:</bold> In both cohorts, levels of CA HIV RNA and DNA strongly correlated (<italic>rho</italic>=0.70 and <italic>rho</italic>=0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (p<sub>adj</sub>=0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (p<sub>adj</sub>=0.048 and p<sub>adj</sub>=0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals.</p><p><bold>CONCLUSIONS:</bold> All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001826</institution-id><institution>ZonMw</institution></institution-wrap></funding-source><award-id>09120011910035</award-id><principal-award-recipient><name><surname>Berkhout</surname><given-names>Ben</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011272</institution-id><institution>FP7 Health</institution></institution-wrap></funding-source><award-id>305522</award-id><principal-award-recipient><name><surname>Reiss</surname><given-names>Peter</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The COBRA study was approved by the institutional review board of the Academic Medical Center (Medisch Ethische Toetsingscommissie, reference number NL 30802.018.09) and a UK Research Ethics Committee (REC) (reference number 13/LO/0584 Stanmore, London). All participants provided written informed consent. The AIMS study was approved by the institutional review board of the Academic Medical Center (protocol number NTR176). The trial is registered at https://www.isrctn.com (ISRCTN97730834). All participants provided written informed consent.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-68174-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>